Performance of a prototype measles IgM rapid diagnostic test (RDT) was evaluated during suspected measles outbreaks in Uganda.
Oral fluid (OF), capillary blood (CAP) and serum samples were collected from participants. OF and CAP were tested using the RDT at patient contact, while usability was assessed through questionnaires administered to health workers, patients, and guardians. Residual OF and IgM-positive RDTs from OF testing underwent measles qRT-PCR at Uganda Virus Research Institute. RDT performance was compared with Siemens anti-measles IgM ELISA performed on sera and with true measles cases, defined as measles ELISA IgM-positive and/or OF RT-PCR positive.
Compared to ELISA, RDT sensitivity and specificity were 97.9% (95% CI: 93.7%–99.3%) and 91.7% (95% CI: 84.7%–95.7%) for CAP, and 96.7% (95% CI: 92.2%–98.6%) and 88.0% (95% CI: 80.7%–92.8%) for OF, respectively. Compared with true measles cases, sensitivity and specificity were 90.4% (95% CI: 84.9%–94.1%) and 89.2% (95% CI: 81.5%–94.0%) for CAP, and 88.5% (95% CI: 82.8%–92.5%) and 86.1% (95% CI: 78.1%–91.5%) for OF, respectively.
OF and CAP sampling, and RDT use were highly acceptable, and health workers reported the RDT could improve measles management. The RDT demonstrated good accuracy and usability for outbreak settings.